Asciminib Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 20 mg, 40 mg
Reference Brands: Scemblix (USA)
Category:
Oncology Cancer Care
Asciminib is available in Tablets
and strengths such as 20 mg, 40 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Asciminib is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Asciminib can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Asciminib is a targeted anticancer medication used for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). It is a novel protein kinase inhibitor with a unique mechanism of action, classified as a STAMP inhibitor (Specifically Targeting the ABL Myristoyl Pocket). Unlike conventional tyrosine kinase inhibitors that bind to the ATP-binding site, asciminib selectively binds to the myristoyl pocket of the BCR-ABL1 protein, resulting in effective and sustained inhibition of leukemic cell growth.
Asciminib is indicated for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase who have previously received two or more tyrosine kinase inhibitors. It is also approved for the treatment of adults with chronic-phase Ph+ CML harboring the T315I mutation, a mutation associated with resistance to multiple standard therapies.
Marketed under the brand name Scemblix, asciminib offers a targeted treatment option for patients with limited therapeutic alternatives. Its distinct mechanism of action supports its use in resistant or refractory cases, contributing to improved disease control and long-term management of chronic myeloid leukemia.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing